ALS2CL: A Protein Targeted for Neurodegenerative Diseases Research

Target Name: ALS2CL

NCBI ID: G259173

ALS2CL

ALS2CL: A Protein Targeted for Neurodegenerative Diseases Research

ALS2CL, also known as ALS2 C-terminal like, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and muscles. It is a member of the ALS2 family of proteins, which are known for their role in intracellular signaling.

ALS2CL is of particular interest as a potential drug target or biomarker because of its involvement in a number of cellular processes that are important for brain health and function. For example, ALS2CL has been shown to play a role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. Additionally, ALS2CL has been implicated in the development and progression of a number of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

One of the key challenges in studying ALS2CL is its complex structure and the difficulty of studying its function in living organisms. To overcome these challenges, researchers have used a variety of techniques to study ALS2CL, including biochemical, cellular, and animal models.

One approach that has been used to study ALS2CL is mass spectrometry, which is a technique that allows researchers to identify and quantify the proteins in a sample. By analyzing the mass spectra of ALS2CL, researchers have been able to determine its molecular weight, as well as the presence and localization of different isoforms of the protein in the brain.

Another approach that has been used to study ALS2CL is live-cell imaging, which allows researchers to visualize the structure and function of the protein in live cells. By using a combination of genetic modification and fluorescence, researchers have been able to label ALS2CL in the brain and observe its changes in response to different stimuli.

In addition to these techniques, researchers have also used computational tools to study ALS2CL. For example, they have used molecular dynamics simulations to determine the three-dimensional structure of ALS2CL and the forces that act on it. These simulations have allowed researchers to gain insight into the mechanisms that regulate ALS2CL function and the factors that influence its activity.

Based on the information that has been gathered so far, ALS2CL is a protein that is worth investigating as a potential drug target or biomarker. Its involvement in the regulation of synaptic plasticity and its association with neurodegenerative diseases make it a promising target for future research. Additionally, its complex structure and the difficulty of studying it in live organisms make it a challenging but rewarding target for researchers.

In conclusion, ALS2CL is a protein that has the potential to be a valuable drug target or biomarker for the study of neurodegenerative diseases. Further research is needed to fully understand its mechanisms of action and to develop effective treatments based on its properties.

Protein Name: ALS2 C-terminal Like

Functions: Acts as a guanine nucleotide exchange factor (GEF) for Rab5 GTPase. Regulates the ALS2-mediated endosome dynamics

The "ALS2CL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALS2CL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets